{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:11:06Z","timestamp":1790349066735,"version":"4.1.0"},"reference-count":65,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Standard treatment of haemophilia A is based on replacing the missing coagulation factor VIII (FVIII) to treat and prevent bleeding episodes. The most challenging complication of FVIII therapy is the development of neutralizing antibodies (inhibitors) that can render treatment ineffective. Eradication of the inhibitor through immune tolerance induction (ITI) remains the most effective strategy for managing these patients. Bypassing agents can be used to help restore haemostasis in inhibitor patients. Several novel agents have recently been developed, such as the FVIII mimetic agent emicizumab, which has been effective in reducing the annualized bleeding rate in haemophilia A patients with inhibitors. When coadministered with repetitive high doses of activated prothrombin complex concentrate (ie &gt;100\u00a0U\/kg\/d for \u226524\u00a0hours), emicizumab was associated with thrombotic microangiopathy and thrombosis events. As a consequence the United Kingdom Haemophilia Centres Doctors' Organisation (UKHCDO) issued the first guidance on the treatment of bleeding episodes in patients receiving emicizumab. To build on and extend this work, a panel of German haemophilia specialists met to discuss the UK guidance, review current evidence and provide additional guidance for German healthcare professionals on how to optimize the management of patients with haemophilia A receiving emicizumab. Recommendations are provided on the use of bypassing and other agents to manage breakthrough bleeding, ITI in the emicizumab era, haemostatic support during surgery and issues relating to laboratory monitoring.<\/jats:p>","DOI":"10.1111\/hae.14010","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:03:47Z","timestamp":1600301027000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel"],"prefix":"10.1111","volume":"27","author":[{"given":"Carmen","family":"Escuriola\u2010Ettingshausen","sequence":"first","affiliation":[{"name":"Hemophilia Centre Rhein\u2010Main \u2013 HZRM Frankfurt\u2010M\u00f6rfelden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Auerswald","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Care in Haemostasis and Thrombosis Professor Hess Children's Hospital Bremen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"K\u00f6nigs","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine Centre for Hemostasis University Hospital Frankfurt Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Kurnik","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haemostasis University Children's Hospital Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Scholz","sequence":"additional","affiliation":[{"name":"Center of Haemostasis Leipzig Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4194-8183","authenticated-orcid":false,"given":"Robert","family":"Klamroth","sequence":"additional","affiliation":[{"name":"Department for Internal Medicine, Vascular Medicine and Haemostaseology Vivantes Klinikum Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1585-4100","authenticated-orcid":false,"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"Institute of Experimental Hematology and Transfusion Medicine University Clinic Bonn Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00780.x"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2011.01.002"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208024"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516437"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-586347"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23957"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-528414"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1521718"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018015842"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01497.x"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01296.x"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)90871-6"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00311.x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12091"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12730"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04349.x"},{"key":"e_1_2_11_18_1","volume-title":"Cross\u2010Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives","author":"German Medical Association (Bunders\u00e4rtztekammer)","year":"2014"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1996.tb01346.x"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03615.x"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1612943"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01880.x"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00469.x"},{"issue":"10","key":"e_1_2_11_24_1","first-page":"45","article-title":"The German Registry of immune tolerance treatment in hemophilia\u20131999 update","volume":"85","author":"Lenk H","year":"2000","journal-title":"Haematologica"},{"issue":"2","key":"e_1_2_11_25_1","first-page":"62","article-title":"Immunotolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunotolerance Protocols","volume":"31","author":"Mariani G","year":"1994","journal-title":"Semin Hematol"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000056717"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13445"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-369132"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.3.983.983"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(08)70003-3"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12263"},{"key":"e_1_2_11_32_1","volume-title":"Guidelines for the management of hemophilia","author":"World Federation of Hematology","year":"2012"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2545-9"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S159297"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0922-6"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001542"},{"key":"e_1_2_11_37_1","unstructured":"Roche Pharma GmbH.Hemlibra\u00ae summary of product characteristics. February 2018.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hemlibra. Accessed December 5 2018."},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.85.85"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13641"},{"key":"e_1_2_11_42_1","unstructured":"Genetech USA Inc.Hemlibra\u00ae (emicizumab\u2010kxwh): our commitment to safety communication.www.emicizumabinfo.com. Accessed June 2019."},{"key":"e_1_2_11_43_1","unstructured":"National Hemophilia Foundation.Recommendation on the use and management of emicizumab\u2010kxwh (Hemlibra\u00ae) for hemophilia A with and without inhibitors. MASAC document #255.https:\/\/www.hemophilia.org\/Researchers\u2010Healthcare\u2010Providers\/Medical\u2010and\u2010Scientific\u2010Advisory\u2010Council\u2010MASAC\/MASAC\u2010Recommendations\/Recommendation\u2010on\u2010the\u2010Use\u2010and\u2010Management\u2010of\u2010Emicizumab\u2010kxwh\u2010Hemlibra\u2010for\u2010Hemophilia\u2010A\u2010with\u2010and\u2010without\u2010Inhibitors. Accessed December 12 2018."},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13495"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-577643"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0800-z"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.185330"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14491"},{"issue":"4","key":"e_1_2_11_49_1","first-page":"575","article-title":"Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy","volume":"12","author":"Rocino A","year":"2014","journal-title":"Blood Transfus"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13762"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0941"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13193"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018015859"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12288"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13819"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115089"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.89.89"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.215129"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25153"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14203"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2017.284356"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117877"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14135"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14022"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113623"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118504"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14010","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.14010","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T02:38:06Z","timestamp":1693190286000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1111\/hae.14010"],"URL":"https:\/\/doi.org\/10.1111\/hae.14010","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,16]]},"assertion":[{"value":"2019-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}